Association of Metformin Use with Cancer-Specific Mortality in Hepatocellular Carcinoma after Curative Resection

Medicine (United States)

Volumn 95, Issue 17, 2016, Pages

  Seo, Young Seok ^a   Kim, Yun Jung ^a   Kim, Mi Sook ^a,b   Suh, Kyung Suk ^c   Kim, Sang Bum ^a   Han, Chul Ju ^a   Kim, Youn Joo ^a,b   Jang, Won Il ^a   Kang, Shin Hee ^b   Tchoe, Ha Jin ^b   Park, Chan Mi ^b   Jo, Ae Jung ^b   Kim, Hyo Jeong ^b   Choi, Jin A ^b   Choi, Hyung Jin ^d   Polak, Michael N ^e   Ko, Min Jung ^b  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b National Evidence Based Healthcare Collaborating Agency   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Seoul National University   (South Korea)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; METFORMIN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; COHORT ANALYSIS; DIABETIC PATIENT; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETREATMENT; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DISEASE FREE SURVIVAL; HEALTH SURVEY; LIVER NEOPLASMS; MORTALITY; RISK; SOUTH KOREA;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DISEASE-FREE SURVIVAL; FEMALE; HEALTH SURVEYS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; METFORMIN; MIDDLE AGED; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK;

EID: 84978204084     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003527     Document Type: Article

References (28)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;9822:1245-1255.
2. Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015;2:127-141.
3. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;2:181-200.
4. Noto H, Goto A, Tsujimoto T, et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012;3:e33411.
5. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010;11:1451-1461.
6. Zhang P, Li H, Tan X, et al. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 2013;3:207-218.
7. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetolo-gia. 2015;3:429-442.
8. Gandini S, Guerrieri-Gonzaga A, Puntoni M, et al. Metformin and breast cancer risk. J Clin Oncol. 2013;7:973-974.
9. Franciosi M, Lucisano G, Lapice E, et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013;8:e71583.
10. Kowall B, Stang A, Rathmann W, et al. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. Pharmacoepidemiol Drug Saf. 2015;24:865-874.
11. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2012;9:778-790.
12. Algire C, Amrein L, Bazile M, et al. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene. 2011;10:1174-1182.
13. Wheaton WW, Weinberg SE, Hamanaka RB, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumor-igenesis. Elife. 2014:e02242.
14. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;21:10269-10273.
15. Kordes S, Pollak MN, Zwinderman AH, et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2015;7:839-847.
16. Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther. 2004;1:2-9.
17. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011;9:33.
18. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;2:81-98.
19. Jung KW, Won YJ, Oh CM, et al. Prediction of cancer incidence and mortality in Korea. Cancer Res Treat. 2015;2:142-148.
20. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;5:373-383.
21. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012;12:2665-2673.
22. Chen TM, Lin CC, Huang PT, et al. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol. 2011;5:858-865.
23. Bhat M, Chaiteerakij R, Harmsen WS, et al. Metformin does not improve survival in patients with hepatocellular carcinoma. World J Gastroenterol. 2014;42:15750-15755.
24. Singh S, Singh PP, Singh AG, et al. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol. 2013;6:881-891.
25. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;2:200-207.
26. Granger BB, Swedberg K, Ekman I, et al. CHARM investigators. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet. 2005;9502:2005-2011.
27. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;4:707-716.
28. Gronich N, Rennert G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol. 2013;11:625-642.